← Back to Clinical Trials
Recruiting Phase 1 NCT07058974

A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation

Trial Parameters

Condition Smokers
Sponsor Icahn School of Medicine at Mount Sinai
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 22
Sex ALL
Min Age 65 Years
Max Age 80 Years
Start Date 2025-08-25
Completion 2026-07-01
Interventions
lamivudinerapamycinExercise Regimen

Brief Summary

This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.

Eligibility Criteria

Inclusion Criteria: * Patients 65-80 years old * Current or former smokers * BMI 25-32 * No cancer requiring active therapy within the last 2 years * No autoimmune disease requiring disease modifying agents * No patients with CKD stage 3/4 or ESRD * No class 3 or 4 heart failure Exclusion Criteria: * Patients may not have cancer requiring active therapy within the last 2 years * Patients may not have autoimmune disease requiring disease modifying agents * Patients may not be receiving immune modifying biologic therapies * Patients may not have chronic kidney disease stage 3/4 or end stage renal disease * Patients may not have a known history of metabolic dysfunction-associated steatohepatitis * Patients may not have a known chronic viral infection such as HIV or active Hepatitis B or C, or a known history of genital HSV. Patients who have spontaneously or through treatment cleared hepatitis B or C are candidates for the trial. If Hepatitis B core ab is positive must document a negative

Related Trials